"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products and key innovative products," said Teva CEO.
Amalia Adler-Waxman, Senior Vice President, Global Head of Sustainability and Head of Corporate Affairs of International Markets at Teva, spoke at the Jerusalem Post's Women Leaders Summit.
The funding agreement will offset program costs for Teva, which will lead the clinical development of the schizophrenia treatment and regulatory process and is responsible for commercialization.
Biolojic is eligible to receive tiered royalties in "mid-single to low-double digit" millions of dollars on product sales should Teva successfully commercialize a therapy.